Patients' clinical characteristics at study entry
Features . | No. of patients (%) . |
|---|---|
| Sex | |
| Male | 11 (31) |
| Female | 24 (69) |
| Ann Arbor stage | |
| IE | 12 (34) |
| IIE | 3 (9) |
| IV | 20 (57) |
| B symptoms | 2 (6) |
| Serum LDH level | |
| Elevated | 3 (9) |
| Unknown | 1 (3) |
| Serum β2-microglobulin level | |
| Elevated | 6 (17) |
| Unknown | 5 (14) |
| More than 1 extranodal site | 7 (20) |
| Nodal involvement | 13 (37) |
| Bone marrow involvement | 9 (26) |
| Intermediate/high to high-risk IPI score | 7 (20) |
| Previous chemotherapy | 11 (31) |
| Primary site* | |
| Stomach | 15 (43) |
| skin/subcutaneous tissue | 7 (20) |
| Salivary gland | 4 (11) |
| Lung | 4 (11) |
| Orbit | 3 (9) |
| Breast | 1 (3) |
| Liver | 1 (3) |
Features . | No. of patients (%) . |
|---|---|
| Sex | |
| Male | 11 (31) |
| Female | 24 (69) |
| Ann Arbor stage | |
| IE | 12 (34) |
| IIE | 3 (9) |
| IV | 20 (57) |
| B symptoms | 2 (6) |
| Serum LDH level | |
| Elevated | 3 (9) |
| Unknown | 1 (3) |
| Serum β2-microglobulin level | |
| Elevated | 6 (17) |
| Unknown | 5 (14) |
| More than 1 extranodal site | 7 (20) |
| Nodal involvement | 13 (37) |
| Bone marrow involvement | 9 (26) |
| Intermediate/high to high-risk IPI score | 7 (20) |
| Previous chemotherapy | 11 (31) |
| Primary site* | |
| Stomach | 15 (43) |
| skin/subcutaneous tissue | 7 (20) |
| Salivary gland | 4 (11) |
| Lung | 4 (11) |
| Orbit | 3 (9) |
| Breast | 1 (3) |
| Liver | 1 (3) |
In 7 of these cases multiple mucosal sites were involved.